Header Logo

Connection

HASHEM EL-SERAG to Retrospective Studies

Back to Details
This is a "connection" page, showing publications HASHEM EL-SERAG has written about Retrospective Studies.
HASHEM EL-SERAG
Connection Strength
2.408
Retrospective Studies
  1. HES V2.0 validation and performance compared to GALAD and ASAP in the HEDS cohort. J Hepatol. 2026 Mar; 84(3):578-586.
    View in: PubMed
    Score: 0.065
  2. A Simple, Interpretable Machine Learning Model Based on Clinical Factors Accurately Predicts Incident Dysplasia or Malignancy in Barrett's Esophagus. Dig Dis Sci. 2025 Aug; 70(8):2739-2749.
    View in: PubMed
    Score: 0.063
  3. HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States. Hepatology. 2025 Feb 01; 81(2):465-475.
    View in: PubMed
    Score: 0.060
  4. The Risk of Hepatocellular Carcinoma in Entecavir Versus Tenofovir Treated US Cohort With Chronic Hepatitis B Virus. Clin Gastroenterol Hepatol. 2023 04; 21(4):1111-1113.e3.
    View in: PubMed
    Score: 0.051
  5. The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States. Clin Gastroenterol Hepatol. 2023 02; 21(2):415-423.e4.
    View in: PubMed
    Score: 0.051
  6. External validation of a model determining risk of neoplastic progression of Barrett's esophagus in a cohort of U.S. veterans. Gastrointest Endosc. 2022 06; 95(6):1113-1122.
    View in: PubMed
    Score: 0.050
  7. Risk for Post-Colonoscopy Irritable Bowel Syndrome in Patients With and Without Antibiotic Exposure: A Retrospective Cohort Study. Clin Gastroenterol Hepatol. 2022 06; 20(6):e1305-e1322.
    View in: PubMed
    Score: 0.049
  8. Prevalence of Barrett's esophagus and performance of societal?screening guidelines in an unreferred primary care population of U.S. veterans. Gastrointest Endosc. 2021 02; 93(2):409-419.e1.
    View in: PubMed
    Score: 0.045
  9. Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. Hepatology. 2020 03; 71(3):808-819.
    View in: PubMed
    Score: 0.044
  10. Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. Hepatology. 2020 01; 71(1):44-55.
    View in: PubMed
    Score: 0.043
  11. The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection. Aliment Pharmacol Ther. 2019 06; 49(11):1442-1447.
    View in: PubMed
    Score: 0.042
  12. Statin Use After Diagnosis of Hepatocellular Carcinoma Is Associated With Decreased Mortality. Clin Gastroenterol Hepatol. 2019 09; 17(10):2117-2125.e3.
    View in: PubMed
    Score: 0.041
  13. Changing Trends in Colorectal Cancers (Detected by Screening, During Screening Intervals, or Associated With Nonadherence) Identify Possible Health Care System Quality Measures. Gastroenterology. 2019 02; 156(3):809-811.
    View in: PubMed
    Score: 0.040
  14. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology. 2018 12; 155(6):1828-1837.e2.
    View in: PubMed
    Score: 0.040
  15. Lessons From Using Culture-Guided Treatment After Referral for Multiple Treatment Failures for Helicobacter pylori Infection. Clin Gastroenterol Hepatol. 2018 09; 16(9):1531-1532.
    View in: PubMed
    Score: 0.038
  16. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017 10; 153(4):996-1005.e1.
    View in: PubMed
    Score: 0.037
  17. The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett's Esophagus. Am J Gastroenterol. 2017 Jul; 112(7):1049-1055.
    View in: PubMed
    Score: 0.036
  18. Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: A United States cohort. J Hepatol. 2016 12; 65(6):1148-1154.
    View in: PubMed
    Score: 0.035
  19. Early outpatient follow-up and 30-day outcomes in patients hospitalized with cirrhosis. Hepatology. 2016 08; 64(2):569-81.
    View in: PubMed
    Score: 0.034
  20. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology. 2016 07; 64(1):130-7.
    View in: PubMed
    Score: 0.034
  21. Epidemiology and outcomes of hepatitis C infection in elderly US Veterans. J Viral Hepat. 2016 09; 23(9):687-96.
    View in: PubMed
    Score: 0.034
  22. The incidence of esophageal adenocarcinoma in a national veterans cohort with Barrett's esophagus. Am J Gastroenterol. 2014 Dec; 109(12):1862-8; quiz 1861, 1869.
    View in: PubMed
    Score: 0.031
  23. Risk of upper gastrointestinal cancers in patients with gastroesophageal reflux disease after a negative screening endoscopy. Clin Gastroenterol Hepatol. 2015 Feb; 13(2):280-6.
    View in: PubMed
    Score: 0.030
  24. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology. 2014 Jul; 60(1):98-105.
    View in: PubMed
    Score: 0.030
  25. Brief report: the length of newly diagnosed Barrett's esophagus may be decreasing. Dis Esophagus. 2015 Jul; 28(5):418-21.
    View in: PubMed
    Score: 0.029
  26. Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology. 2013 Aug; 58(2):538-45.
    View in: PubMed
    Score: 0.028
  27. Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Hepatology. 2013 May; 57(5):1858-68.
    View in: PubMed
    Score: 0.027
  28. Practice patterns of surveillance endoscopy in a Veterans Affairs database of 29,504 patients with Barrett's esophagus. Gastrointest Endosc. 2012 Oct; 76(4):743-55.
    View in: PubMed
    Score: 0.026
  29. Risk of colorectal cancer among Caucasian and African American veterans with ulcerative colitis. Inflamm Bowel Dis. 2012 Jun; 18(6):1011-7.
    View in: PubMed
    Score: 0.025
  30. Level of a-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011 Nov; 9(11):989-94.
    View in: PubMed
    Score: 0.024
  31. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med. 2011 Jan 18; 154(2):85-93.
    View in: PubMed
    Score: 0.024
  32. Dietary history and physical activity and risk of advanced liver disease in veterans with chronic hepatitis C infection. Dig Dis Sci. 2011 Jun; 56(6):1835-47.
    View in: PubMed
    Score: 0.023
  33. Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. Am J Gastroenterol. 2011 Mar; 106(3):483-91.
    View in: PubMed
    Score: 0.023
  34. Underdiagnosis of Lynch syndrome involves more than family history criteria. Clin Gastroenterol Hepatol. 2010 Jun; 8(6):523-9.
    View in: PubMed
    Score: 0.022
  35. Diagnostic yield of oesophagogastroduodenoscopy in children with abdominal pain. Aliment Pharmacol Ther. 2009 Sep 15; 30(6):662-9.
    View in: PubMed
    Score: 0.021
  36. The extent and determinants of prescribing and adherence with acid-reducing medications: a national claims database study. Am J Gastroenterol. 2009 Sep; 104(9):2161-7.
    View in: PubMed
    Score: 0.021
  37. The utility of evaluating low serum albumin gradient ascites in patients with cirrhosis. Am J Gastroenterol. 2009 Jun; 104(6):1401-5.
    View in: PubMed
    Score: 0.021
  38. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. Hepatology. 2009 Jan; 49(1):116-23.
    View in: PubMed
    Score: 0.020
  39. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008 Nov; 49(5):831-44.
    View in: PubMed
    Score: 0.020
  40. Hepatitis vaccination in patients with hepatitis C: practice and validation of codes at a large Veterans Administration Medical Centre. Aliment Pharmacol Ther. 2008 Nov 01; 28(9):1078-87.
    View in: PubMed
    Score: 0.020
  41. Lagtimes in diagnosis and treatment of colorectal cancer: determinants and association with cancer stage and survival. Aliment Pharmacol Ther. 2008 Nov 01; 28(9):1166-74.
    View in: PubMed
    Score: 0.020
  42. The use of acid-decreasing medication in veteran patients with gastro-oesophageal reflux disorder with and without Barrett's oesophagus. Aliment Pharmacol Ther. 2008 Jun; 27(12):1293-9.
    View in: PubMed
    Score: 0.019
  43. Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era. J Clin Oncol. 2008 Jan 20; 26(3):474-9.
    View in: PubMed
    Score: 0.019
  44. The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Aliment Pharmacol Ther. 2008 Feb 01; 27(3):274-82.
    View in: PubMed
    Score: 0.019
  45. Utilization of screening for hepatocellular carcinoma in the United States. J Clin Gastroenterol. 2007 Sep; 41(8):777-82.
    View in: PubMed
    Score: 0.019
  46. The impact of curative intent surgery on the survival of pancreatic cancer patients: a U.S. Population-based study. Am J Gastroenterol. 2007 Jul; 102(7):1377-82.
    View in: PubMed
    Score: 0.018
  47. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr. 2007 Mar; 150(3):262-7, 267.e1.
    View in: PubMed
    Score: 0.018
  48. The prevalence of suspected Barrett's esophagus in children and adolescents: a multicenter endoscopic study. Gastrointest Endosc. 2006 Nov; 64(5):671-5.
    View in: PubMed
    Score: 0.018
  49. Performance of Ulcer Features in Predicting Malignancy Among Gastric Ulcers Diagnosed on Upper Endoscopy. J Clin Gastroenterol. 2026 Jan 01; 60(1):40-46.
    View in: PubMed
    Score: 0.017
  50. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol. 2006 Jan; 44(1):158-66.
    View in: PubMed
    Score: 0.016
  51. Eradication Rates of Empiric Helicobacter pylori Treatment Regimens by Race/Ethnicity in a Predominantly Immigrant U.S. Population. Helicobacter. 2025 Nov-Dec; 30(6):e70095.
    View in: PubMed
    Score: 0.016
  52. Physical and psychosocial contributors to quality of life in veterans with hepatitis C not on antiviral therapy. J Clin Gastroenterol. 2005 Sep; 39(8):731-6.
    View in: PubMed
    Score: 0.016
  53. Postoperative 30-day mortality following surgical resection for colorectal cancer in veterans: changes in the right direction. Dig Dis Sci. 2005 Sep; 50(9):1722-8.
    View in: PubMed
    Score: 0.016
  54. High Risk of Persistence and Risk of Dysplasia After Diagnosis of Ultrashort Barrett's Esophagus. Am J Gastroenterol. 2025 Nov 01; 120(11):2520-2528.
    View in: PubMed
    Score: 0.016
  55. Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. J Hepatol. 2005 Mar; 42(3):309-14.
    View in: PubMed
    Score: 0.016
  56. Survival in hepatitis C and HIV co-infection: a cohort study of hospitalized veterans. Clin Gastroenterol Hepatol. 2005 Feb; 3(2):175-83.
    View in: PubMed
    Score: 0.016
  57. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol. 2005 Jan; 100(1):56-63.
    View in: PubMed
    Score: 0.015
  58. Prevalence and Outcomes of Emergency Presentations of Colorectal Cancer in Veterans Affairs Health Care System. Dig Dis Sci. 2025 Jan; 70(1):177-190.
    View in: PubMed
    Score: 0.015
  59. Interval Advanced Adenomas and Neoplasia in Patients with Negative Colonoscopy Following Positive Stool-Based Colorectal Cancer Screening Test. Dig Dis Sci. 2025 Jan; 70(1):350-359.
    View in: PubMed
    Score: 0.015
  60. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Arch Intern Med. 2004 Nov 22; 164(21):2349-54.
    View in: PubMed
    Score: 0.015
  61. Phase 3 Validation of PAaM for Hepatocellular Carcinoma Risk Stratification in Cirrhosis. Gastroenterology. 2025 Mar; 168(3):556-567.e7.
    View in: PubMed
    Score: 0.015
  62. GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. JAMA Intern Med. 2024 Nov 01; 184(11):1314-1323.
    View in: PubMed
    Score: 0.015
  63. Outcomes of surgical fundoplication in children. Clin Gastroenterol Hepatol. 2004 Nov; 2(11):978-84.
    View in: PubMed
    Score: 0.015
  64. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol. 2004 Oct; 99(10):1877-83.
    View in: PubMed
    Score: 0.015
  65. The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy. Aliment Pharmacol Ther. 2004 Jun 15; 19(12):1255-60.
    View in: PubMed
    Score: 0.015
  66. Childhood GERD is a risk factor for GERD in adolescents and young adults. Am J Gastroenterol. 2004 May; 99(5):806-12.
    View in: PubMed
    Score: 0.015
  67. Is the length of newly diagnosed Barrett's esophagus decreasing? The experience of a VA Health Care System. Clin Gastroenterol Hepatol. 2004 Apr; 2(4):296-300.
    View in: PubMed
    Score: 0.015
  68. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology. 2004 Mar; 39(3):798-803.
    View in: PubMed
    Score: 0.015
  69. Emergency Presentations Predict Worse Outcomes Among Patients with Pancreatic Cancer. Dig Dis Sci. 2024 Feb; 69(2):603-614.
    View in: PubMed
    Score: 0.014
  70. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003 Nov 18; 139(10):817-23.
    View in: PubMed
    Score: 0.014
  71. The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias? Am J Gastroenterol. 2003 Nov; 98(11):2535-42.
    View in: PubMed
    Score: 0.014
  72. Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease. J Hepatol. 2023 03; 78(3):493-500.
    View in: PubMed
    Score: 0.013
  73. Longitudinal Associations of Risk Factors and Hepatocellular Carcinoma in Patients With Cured Hepatitis C Virus Infection. Am J Gastroenterol. 2022 11 01; 117(11):1834-1844.
    View in: PubMed
    Score: 0.013
  74. Risk factors for the severity of erosive esophagitis in Helicobacter pylori-negative patients with gastroesophageal reflux disease. Scand J Gastroenterol. 2002 Aug; 37(8):899-904.
    View in: PubMed
    Score: 0.013
  75. Risk of Hepatocellular Carcinoma in Patients with Various HFE Genotypes. Dig Dis Sci. 2023 01; 68(1):312-322.
    View in: PubMed
    Score: 0.013
  76. Clinical Course and Outcomes of Patients with Nonalcoholic Fatty Liver Disease-Related Hepatocellular Cancer (NAFLD-HCC). Dig Dis Sci. 2023 03; 68(3):1060-1070.
    View in: PubMed
    Score: 0.013
  77. Missed Opportunities for Screening or Surveillance Among Patients with Newly Diagnosed Non-cardia Gastric Adenocarcinoma. Dig Dis Sci. 2023 03; 68(3):761-769.
    View in: PubMed
    Score: 0.013
  78. Comparative Effectiveness of Surveillance Colonoscopy Intervals on Colorectal Cancer Outcomes in a National Cohort of Patients with Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2022 12; 20(12):2848-2857.e2.
    View in: PubMed
    Score: 0.013
  79. Race/Ethnicity and Birthplace as Risk Factors for Gastric Intestinal Metaplasia in a Multiethnic United States Population. Am J Gastroenterol. 2022 02 01; 117(2):280-287.
    View in: PubMed
    Score: 0.013
  80. Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population. Am J Drug Alcohol Abuse. 2022 07 04; 48(4):445-453.
    View in: PubMed
    Score: 0.013
  81. Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. Hepatology. 2022 06; 75(6):1420-1428.
    View in: PubMed
    Score: 0.013
  82. Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States. J Hepatol. 2022 02; 76(2):294-301.
    View in: PubMed
    Score: 0.012
  83. Gastroesophageal reflux disease is a risk factor for laryngeal and pharyngeal cancer. Am J Gastroenterol. 2001 Jul; 96(7):2013-8.
    View in: PubMed
    Score: 0.012
  84. Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis. Am J Gastroenterol. 2001 Jul; 96(7):2206-10.
    View in: PubMed
    Score: 0.012
  85. Prevalence and Predictors of Missed Dysplasia on Index Barrett's Esophagus Diagnosing Endoscopy in a Veteran Population. Clin Gastroenterol Hepatol. 2022 04; 20(4):e876-e889.
    View in: PubMed
    Score: 0.012
  86. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000 Nov 27; 160(21):3227-30.
    View in: PubMed
    Score: 0.012
  87. Development, Validation, and Evaluation of a Simple Machine Learning Model to Predict Cirrhosis Mortality. JAMA Netw Open. 2020 11 02; 3(11):e2023780.
    View in: PubMed
    Score: 0.012
  88. Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes. Hepatology. 2020 10; 72(4):1242-1252.
    View in: PubMed
    Score: 0.012
  89. External Validation of Four Point-of-Care Noninvasive Scores for Predicting Advanced Hepatic Fibrosis in a Predominantly Hispanic NAFLD Population. Dig Dis Sci. 2021 07; 66(7):2387-2393.
    View in: PubMed
    Score: 0.011
  90. Factors Associated With Delay of Diagnosis of Hepatocellular Carcinoma in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2021 08; 19(8):1679-1687.
    View in: PubMed
    Score: 0.011
  91. Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population. Antiviral Res. 2020 02; 174:104698.
    View in: PubMed
    Score: 0.011
  92. Use of Acid-Suppressant Medications After Diagnosis Increases Mortality in a Subset of Gastrointestinal Cancer Patients. Dig Dis Sci. 2020 09; 65(9):2691-2699.
    View in: PubMed
    Score: 0.011
  93. Prevalence of Helicobacter pylori Positive Non-cardia Gastric Adenocarcinoma Is Low and Decreasing in a US Population. Dig Dis Sci. 2020 08; 65(8):2403-2411.
    View in: PubMed
    Score: 0.011
  94. Risk Trajectories for Readmission and Death After Cirrhosis-Related Hospitalization. Dig Dis Sci. 2019 06; 64(6):1470-1477.
    View in: PubMed
    Score: 0.010
  95. Missed Opportunities for Screening and Surveillance of Barrett's Esophagus in Veterans with Esophageal Adenocarcinoma. Dig Dis Sci. 2019 02; 64(2):367-372.
    View in: PubMed
    Score: 0.010
  96. Prior Diagnosis of Barrett's Esophagus Is Infrequent, but Associated with Improved Esophageal Adenocarcinoma Survival. Dig Dis Sci. 2018 11; 63(11):3112-3119.
    View in: PubMed
    Score: 0.010
  97. Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system. J Viral Hepat. 2018 11; 25(11):1270-1279.
    View in: PubMed
    Score: 0.010
  98. Long-term follow up of patients with obscure gastrointestinal bleeding examined with video capsule endoscopy. Medicine (Baltimore). 2018 Jul; 97(29):e11429.
    View in: PubMed
    Score: 0.010
  99. The Association Between Statin Use After Diagnosis and Mortality Risk in Patients With Esophageal Cancer: A Retrospective Cohort Study of United States Veterans. Am J Gastroenterol. 2018 09; 113(9):1310.
    View in: PubMed
    Score: 0.010
  100. Factors Associated With Recurrence of Barrett's Esophagus After Radiofrequency Ablation. Clin Gastroenterol Hepatol. 2019 01; 17(1):65-72.e5.
    View in: PubMed
    Score: 0.010
  101. Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists. Dig Dis Sci. 2018 06; 63(6):1551-1557.
    View in: PubMed
    Score: 0.010
  102. Determinants and Outcomes of Hospice Utilization Among Patients with Advance-Staged Hepatocellular Carcinoma in a Veteran Affairs Population. Dig Dis Sci. 2018 05; 63(5):1173-1181.
    View in: PubMed
    Score: 0.010
  103. Associations between different forms of gastro-oesophageal reflux disease. Gut. 1997 Nov; 41(5):594-9.
    View in: PubMed
    Score: 0.009
  104. Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents. Aliment Pharmacol Ther. 2017 11; 46(10):992-1000.
    View in: PubMed
    Score: 0.009
  105. Association Between Laparoscopic Antireflux Surgery and Recurrence of Gastroesophageal Reflux. JAMA. 2017 09 12; 318(10):939-946.
    View in: PubMed
    Score: 0.009
  106. Role of Age and Race in the Risk of Hepatocellular Carcinoma in Veterans With Hepatitis B Virus Infection. Clin Gastroenterol Hepatol. 2018 02; 16(2):252-259.
    View in: PubMed
    Score: 0.009
  107. Risk and Predictors of Variceal Bleeding in Cirrhosis Patients Receiving Primary Prophylaxis With Non-Selective Beta-Blockers. Am J Gastroenterol. 2016 12; 111(12):1778-1787.
    View in: PubMed
    Score: 0.009
  108. Transarterial bland versus chemoembolization for hepatocellular carcinoma: rethinking a gold standard. J Surg Res. 2016 Feb; 200(2):552-9.
    View in: PubMed
    Score: 0.008
  109. Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology. 2014 Dec; 60(6):1871-8.
    View in: PubMed
    Score: 0.008
  110. The quality of care provided to patients with varices in the department of Veterans Affairs. Am J Gastroenterol. 2014 Jul; 109(7):934-40.
    View in: PubMed
    Score: 0.007
  111. Accuracy of diagnostic codes for identifying patients with ulcerative colitis and Crohn's disease in the Veterans Affairs Health Care System. Dig Dis Sci. 2014 Oct; 59(10):2406-10.
    View in: PubMed
    Score: 0.007
  112. The impact of HIV viral control on the incidence of HIV-associated anal cancer. J Acquir Immune Defic Syndr. 2013 Aug 15; 63(5):631-8.
    View in: PubMed
    Score: 0.007
  113. Association between facility characteristics and the process of care delivered to patients with hepatitis C virus infection. Dig Dis Sci. 2014 Feb; 59(2):273-81.
    View in: PubMed
    Score: 0.007
  114. Esophageal eosinophilia after radiofrequency ablation for Barrett's esophagus. Dis Esophagus. 2013 Sep-Oct; 26(7):674-7.
    View in: PubMed
    Score: 0.007
  115. Process of care for hepatitis C infection is linked to treatment outcome and virologic response. Clin Gastroenterol Hepatol. 2012 Nov; 10(11):1270-1277.e3.
    View in: PubMed
    Score: 0.007
  116. The performance of process measures in hepatitis C. Am J Gastroenterol. 2012 Oct; 107(10):1512-21.
    View in: PubMed
    Score: 0.007
  117. Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol. 2009 Dec; 7(12):1299-304.
    View in: PubMed
    Score: 0.005
  118. Using a multifaceted approach to improve the follow-up of positive fecal occult blood test results. Am J Gastroenterol. 2009 Apr; 104(4):942-52.
    View in: PubMed
    Score: 0.005
  119. Prevalence of endoscopic findings of erosive esophagitis in children: a population-based study. J Pediatr Gastroenterol Nutr. 2008 Aug; 47(2):141-6.
    View in: PubMed
    Score: 0.005
  120. Complications of pediatric colonoscopy: a five-year multicenter experience. Clin Gastroenterol Hepatol. 2008 May; 6(5):515-20.
    View in: PubMed
    Score: 0.005
  121. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 2007 Oct; 5(10):1221-8.
    View in: PubMed
    Score: 0.005
  122. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA. 2007 May 09; 297(18):2010-7.
    View in: PubMed
    Score: 0.005
  123. Complications of pediatric EGD: a 4-year experience in PEDS-CORI. Gastrointest Endosc. 2007 Feb; 65(2):213-21.
    View in: PubMed
    Score: 0.004
  124. The impact of immigration on the increasing incidence of hepatocellular carcinoma in the United States. Aliment Pharmacol Ther. 2004 Aug 15; 20(4):445-50.
    View in: PubMed
    Score: 0.004
  125. Celiac sprue among US military veterans: associated disorders and clinical manifestations. Dig Dis Sci. 1999 May; 44(5):966-72.
    View in: PubMed
    Score: 0.003
  126. Colonic mucosal abnormalities associated with oral sodium phosphate solution. Gastrointest Endosc. 1996 May; 43(5):463-6.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.